兰州大学机构库 >学院待认领
达沙替尼不同治疗方案治疗慢性髓细胞白血病疗效的Meta分析
Alternative TitleEffectiveness of Different Regimes of Dasatinib for Chronic Myeloid Leukemia: A Meta-Analysis
郭敏
Thesis Advisor席亚明
2013-05-21
Degree Grantor兰州大学
Place of Conferral兰州
Degree Name硕士
Keyword达沙替尼 慢性髓细胞白血病 Meta分析 系统评价 随机对照试验
Abstract目的 系统评价达沙替尼140mg,1/日和70mg,2/日治疗慢性髓细胞白血病的疗效。方法 计算机检索Embase(1974-2011.11)、PubMed(1966-2011.11)、Cochrane library(2011年第11期)、CBM(1979-2011.11)、VIP(1989-2011.11)、CNKI(1994-2011.11)和WanFang Data(1997-2011.11)等数据库并手工检索相关领域的杂志,查找达沙替尼140mg,1/日和70mg,2/日治疗慢性髓细胞白血病(CML)的随机对照试验。对符合纳入标准的随机对照试验,由两位评价员按Cochrane系统评价的方法,独立进行资料提取、质量评价并交叉核对后,采用RevMan 5.1软件进行Meta分析。结果 共纳入4个研究,862例患者。Meta分析结果显示,两种方案长期治疗CML时,两者完全血液学缓解(CHR)[RR=0.97,95%CI(0.88,1.07),P=0.58] 、完全细胞遗传学缓解(CCyR)[RR=0.94,95%CI(0.80,1.11),P=0.47]及主要细胞遗传学缓解(MCyR)[RR=0.99,95%CI(0.86,1.13),P=0.86] 差异均无统计学意义;短期治疗CML慢性期时,CHR、CCyR及MCyR差异也均无统计学意义;对长期治疗CML慢性期及进展期进行亚组分析,结果显示其CHR、CCyR及MCyR差异均无统计学意义。结论 达沙替尼140mg,1/日和70mg,2/日治疗CML的疗效相似。
Other AbstractObjective To systematically evaluate the effectiveness of dasatinib 140mg qd and 70mg bid for CML. Methods The RCTs were retrieved from Embase (1974-2011.11), Pubmed (1966-2011.11), the Cochrane Library (Issue 11, 2011), CBM (1979-2011.11), VIP (1989-2011.11), CNKI (1994-2011.11), Wanfang Data (1997-2011.11) and references listed in all articles. RCTs meeting inclusive criteria were included the data were extracted, the quality was evaluated and cross-checked by two reviewers independently according to Cochrane Handbook for Systematic Reviews of Interventions and then meta-analyses were conducted using RevMan 5.1 software. Results A total of four studies and 862 patients were included. Results of meta-analyses showed that when dasatinib was used in the long-term treatment of CML, no significant difference was found between 140mg qd and 70mg bid in the CHR (RR=0.97, 95%CI 0.88 to 1.07,P=0.58), CCyR (RR=0.94,95%CI 0.80 to 1.11,P=0.47) and MCyR (RR=0.99,95%CI 0.86 to 1.13,P=0.86). In the short-term treatment of CML, there were no significant differences in the CHR, CCyR and MCyR. The subgroup analyses on the long-term treatment of CML in both chronic phase and advanced phase showed that there were no significant differences in the CHR, MCyR and CCyR. Conclusion In the effectiveness of dasatinib for CML, the dose of 140mg qd is similar to the dose of 70mg bid.
URL查看原文
Language中文
Document Type学位论文
Identifierhttps://ir.lzu.edu.cn/handle/262010/223707
Collection学院待认领
Affiliation临床医学院
Recommended Citation
GB/T 7714
郭敏. 达沙替尼不同治疗方案治疗慢性髓细胞白血病疗效的Meta分析[D]. 兰州. 兰州大学,2013.
Files in This Item:
There are no files associated with this item.
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
Altmetrics Score
Google Scholar
Similar articles in Google Scholar
[郭敏]'s Articles
Baidu academic
Similar articles in Baidu academic
[郭敏]'s Articles
Bing Scholar
Similar articles in Bing Scholar
[郭敏]'s Articles
Terms of Use
No data!
Social Bookmark/Share
No comment.
Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.